With the increasing prevalence of microorganisms with multiple resistance to antibiotics or other agents, the relapse threatens the pre-antibiotic era. The search for new options for effective control of infectious diseases is becoming increasingly important. Recently, the World Health Organization (WHO) published a list of the ten most dangerous microorganisms, including members of the genera *Acinetobacter*, *Pseudomonas*, *Streptococcus*, *Staphylococcus* or *Enterobacter*. Besides, the WHO has developed a tool for determining which diseases and pathogens should be prioritized for research and development in public health emergency contexts. There are also many viral diseases including Ebola and Marburg virus, Zika and Middle East respiratory syndrome coronavirus (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS), among others. Interestingly disease X is in the list and it exemplifies how an important epidemic could be caused by a microorganism that by now was not known to be an etiologic agent of human disease, and thus the R&D Blueprint seeks to enable cross-cutting R&D preparation that is also relevant for an unknown disease.

With the help of proteomics, the function of pathogens and hosts can now be considered globally with the genome sequences as the basis for the monitoring of proteins, their modifications and interactions. While considerable progress has been made in mass spectrometry in the identification and quantification of proteins, the analysis of host-pathogen interactions has analytical limits due to the numerically unfavorable relationship between host and pathogen proteins. However, the new technical achievements mean that it is increasingly possible to characterize complex mixtures and thus open up new possibilities.

In order to promote the collaboration between scientists working on proteomic studies related to infectious diseases caused by virus, bacteria, fungi and parasites, the Human Infectious Diseases initiative in the context of the Human Proteome Project (HID-HPP) was stablished in 2014. New diagnostic tests, therapeutic agents and vaccines are required to control these infectious diseases. International collaboration of scientists working in infectious diseases and proteomics is therefore essential to promote these researches. This special issue includes 12 original papers and 3 reviews from the topic of infectious diseases showing different proteomic approaches used in this field.

There are four articles devoted to the study of different bacteria: M*ycobacterium smegmatis, Escherichia coli, Streptococcus suis* and *Aeromonas hydrophila.* In one of these studies, the authors demonstrated that vitamin C treatment causes major changes in the proteome and phosphoproteome of *M. smegmatis.* Bioinformatics analysis pointed toward a novel coordinated network of signaling and regulatory responses, involving a decline in mycobacterial growth rate in preparation for dormancy. Another study carried out a proteomic comparison of three clinical diarrhoeagenic drug-resistant *E. coli* isolates and allowed the characterization of the virulence and antimicrobial resistance attributes of the different strains. Infection and adaption-based proteomic changes of *Streptococcus suis* serotype 2 in a pig model was addressed by other researchers and a virulence associated network was established using the enriched differential abundance proteins and the previously reported putative virulence factors associated with *in vivo* infection. In addition, a quantitative proteomic analysis of *A. hydrophila* showed that chemotaxis is involved in chlortetracycline resistance and may contribute to the development of more effective future treatments.

Two papers are focused on the host and bacterial response. One of the researches analyzing nasal polyp tissue reveled that *Staphylococcus aureus* controls interleukin-5 release in upper airway inflammation due to the secretion of staphylococcal virulence factors. The other investigation revealed that symbiont bacterial strain affects dendritic cells proteome in a distinct way of pathobiont bacteria, by downregulating inflammatory proteins and activating anti-inflammatory upstream regulators.

Another work addresses by mass spectrometry-based Shiga toxin identification in *E. coli* strains using receptor-analogue based affinity enrichment.

Three studies about parasites are included and unveiled the dynamic molecular events associated to *Plasmodium berghei* gametogenesis, the differences between *Neospora caninum* isolates throughout the tachyzoite lytic cycle and the proteomic profile of the brain of mice with experimental cerebral malaria. In addition, an article about the impact of protein extraction methods for human gut metaproteomics reflects the high interest of the microbiota for the scientific community.

Finally, three reviews are devoted to *Candida albicans*, *Leptospira* and the macrophage response to viral infection. In the *C. albicans* paper, the authors reviewed the published proteomic studies that have examined *C. albicans* extracellular proteins, including the cell surface proteins and the secreted proteins. These proteins are the initial points of contact between the fungus and the host and thus very interesting for the development of diagnosis methods and the discovery of vaccine candidates. In the *Leptospira* review the authors addressed the contribution to leptospirosis knowledge based on proteomic strategies. From the initial 2-DE approach to more advanced MS technologies. Concerning the macrophage response to viral infection paper, the authors reviewed how proteomic studies have enhanced the understanding of macrophage response to viral infection with special focus on Influenza A and human immunodeficiency viruses, and virus infections of swine.

To close, a proteomic approach based on the EVA (ethyl vinyl acetate) film was used to interrogate the death registries of the plague epidemic of 1630 that were stored at the Archivio di Stato of Milano.Unlabelled Image
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She leads the group "Host pathogen interaction; Human Proteome Project" (<http://www.ucm.es/candida>). The main research lines in her group are related to proteomics of the *Candida*-host interaction to improve the knowledge on molecular mechanisms of host innate and acquired immune responses in candidiasis. The main objectives are to search novel biomarker and vaccine candidates for invasive candidiasis and to monitor the activation of signaling pathways in innate immune cells interacting with *Candida* cells. The group is also involved in the Human Proteome Project (HPP) where Spain is responsible for developing SRM methods to detect proteins encoded in chromosome 16 (chromosome-centric HPP, or C-HPP) and try, at the same time to integrate the acquired methodology with the biology/disease branch of the HPP, (B/D-HPP) by focusing towards the proteins involved in the defense against candidiasis and mycoses in general. She is co-chair of the HUPO Infectious Initiative (<https://www.hupo.org/Infectious-Disease-Initiative>).
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In 2000 Frank Schmidt started his scientific career at the Max Planck Institute for Infection Biology in Berlin, Germany and finished his PhD in 2003. After working at the Center for Human Proteomics in Dublin in 2004 for a short period, he moved to the University of Oslo in Norway. There he dealt with apoptotic processes of human cells and the proteasome complex system, which both play an important role in the host response. He then moved to the Helmholtz Center Leipzig before moving to Greifswald in 2007 as group leader for proteomics. To date he is a Group Leader at the Medical University Greifswald, where his group investigates mechanisms of bacterial pathogens to discover potential targets for vaccination. In the past 17 years he gained a deep knowledge in proteomics and immunoproteomics and its application in the characterization of the pathophysiology of bacteria during infection. He also developed many FACS and proteomics related methods to understand host-pathogen interactions. Beside identification and quantitation of cytosolic proteins he also investigated the virulent potential of membrane associated or secreted proteins which act as antagonist to the human immune system. Dr. Schmidt is a member of HUPO\'s Infectious Disease Initiative, editor for several proteome or microbiology related journals and guest professor in Austria.
